Dantrolene low-volume - Eagle Pharmaceuticals

Drug Profile

Dantrolene low-volume - Eagle Pharmaceuticals

Alternative Names: Dantrolene; Dantrolene sodium; EP-4104; Ryanodex

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lyotropic Therapeutics
  • Developer Eagle Pharmaceuticals
  • Class Antispastics; Furans; Hydantoins; Imidazolidines; Muscle relaxants; Nitrophenols; Small molecules
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fever; Wounds
  • New Molecular Entity No

Highest Development Phases

  • Marketed Fever
  • Preregistration Wounds
  • Preclinical Neurological disorders

Most Recent Events

  • 26 Feb 2018 Eagle Pharmaceuticals plans clinical trial for Exertional heat stroke (wounds) in August 2018
  • 07 Feb 2018 9232960 - added patent info to the patent sec and HE
  • 17 Oct 2017 Eagle Pharmaceuticals has patent protection for dantrolene in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top